 |
 |
 |
| |
|
News & Resources > Other issues > Refs 1-50
References 1 - 50
|
Refs 1 - 50 |
Refs 51 - 100 |
Refs 101 - 150 |
Refs 151 - 200 |
Refs 201 - 250 |
Refs 251 - 291 |
Note:
[return to text]
- goes to the last page in
viewed in COPD-X regardless
of reference number.
|
1
|
Australian
Institute of Health and Welfare,
Chronic diseases and associated risk factors in
Australia,
2006.
2006, AIHW: Canberra. |
|
2
|
The Thoracic
Society of Australia and New Zealand New Zealand Branch and Asthma
and Respiratory Foundation of New Zealand,
The burden of COPD in New Zealand.
2003. |
|
3
|
The
Australian Lung Foundation, Case
Statement. Chronic Obstructive Pulmonary Disease (COPD). 2001,
The Australian Lung Foundation: Brisbane. |
|
4
|
Crockett,
A., J. Cranston, and J. Moss, Chronic
obstructive pulmonary disease (COPD). Economic Case Statement.
2002. p. 5. |
|
5
|
Wagner, E.H.,
B.T. Austin, and M. Von Korff,
Organizing care for patients with chronic illness. Milbank Q,
1996. 74(4): p. 511-44. |
|
6
|
National
Health and Medical Research Council, A
guide to the Development, Implementation and Evaluation of Clinical
Practice Guidelines. 1998, NHMRC: Canberra. |
|
7
|
NHLBI/WHO
Workshop Report, Global Initiative for
Chronic Obstructive Pulmonary Disease (GOLD):
Global strategy for the diagnosis, management and prevention of
chronic obstructive pulmonary disease.
April 2001, National Institutes of Health - National Heart, Lung and
Blood Institute: Bethesda, MD. |
|
8
|
Fletcher, C.
and R. Peto, The natural history of
chronic airflow obstruction. Br Med J, 1977.
1(6077): p. 1645-8. |
|
9
|
Burrows, B.,
et al., Quantitative relationships
between cigarette smoking and ventilatory function. American Rev
Respir Dis, 1977. 115(2): p.
195-205. |
|
10
|
Global
Initative for Chronic Obstructive Lung Disease,
Global Strategy for the Diagnosis,
Management, and Prevention of Chronic Obstructive Pulmonary Disease
(Updated 2007). p. 2. |
|
11
|
Global
Initiative for Chronic Obstructive Lung Disease (GOLD),
Global Strategy for the Diagnosis,
Management and Prevention of COPD. 2006. |
|
12
|
Matheson,
M.C., et al., Biological dust exposure
in the workplace is a risk factor for chronic obstructive pulmonary
disease. Thorax, 2005. 60(8):
p. 645-51. |
|
13
|
Gan, W.Q.,
et al., Female smokers beyond the
perimenopausal period are at increased risk of chronic obstructive
pulmonary disease: a systematic review and meta-analysis. Respir
Res, 2006. 7: p. 52. |
|
14
|
Peto, R., et
al., The relevance in adults of
air-flow obstruction, but not of mucus hypersecretion, to mortality
from chronic lung disease. Results from 20 years of prospective
observation. Am Rev Respir Dis, 1983.
128(3): p. 491-500. |
|
15
|
Casanova,
C., et al., Inspiratory-to-total lung
capacity ratio predicts mortality in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med, 2005.
171(6): p. 591-7. |
|
16
|
Celli, B.R.,
et al., The body-mass index, airflow
obstruction, dyspnea, and exercise capacity index in chronic
obstructive pulmonary disease. N Engl J Med, 2004.
350(10): p. 1005-12. |
|
17
|
Connors,
A.F., Jr., et al., Outcomes following
acute exacerbation of severe chronic obstructive lung disease. The
SUPPORT investigators (Study to Understand Prognoses and Preferences
for Outcomes and Risks of Treatments) [published erratum appears in
Am J Respir Crit Care Med 1997;155:386]. Am J Respir Crit Care
Med, 1996. 154(4 Pt 1): p. 959-67. |
|
18
|
National
Emphysema Treatment Trial Research, G.,
Patients at High Risk of Death after
Lung-Volume-Reduction Surgery. N Engl J Med, 2001.
345(15): p. 1075-1083. |
|
19
|
Tashkin,
D.P., et al., Methacholine reactivity
predicts changes in lung function over time in smokers with early
chronic obstructive pulmonary disease. The Lung Health Study
Research Group. Am J Respir Crit Care Med, 1996.
153(6 Pt 1): p. 1802-11. |
|
20
|
Anthonisen,
N.R., J.E. Connett, and R.P. Murray,
Smoking and lung function of Lung Health Study participants after 11
years. Am J Respir Crit Care Med, 2002.
166(5): p. 675-9. |
|
21
|
Medical
Research Council Working Party, Long
term domiciliary oxygen therapy in chronic hypoxic cor pulmonale
complicating chronic bronchitis and emphysema. Report of the Medical
Research Council Working Party. Lancet, 1981.
1(8222): p. 681-6. |
|
22
|
Nocturnal
Oxygen Therapy Trial Group, Continuous
or nocturnal oxygen therapy in hypoxemic chronic obstructive lung
disease: a clinical trial. Ann Intern Med, 1980.
93(3): p. 391-8. |
|
23
|
Georgopoulos, D. and N.R. Anthonisen,
Symptoms and signs of COPD, in
Chronic Obstructive Pulmonary Disease, N.S. Cherniack, Editor.
1990, WB Saunders: Toronto. p. 357-363. |
|
24
|
Thompson,
A.B., et al., Aerosolized
beclomethasone in chronic bronchitis. Improved pulmonary function
and diminished airway inflammation. Am Rev Respir Dis, 1992.
146(2): p. 389-95. |
|
25
|
Bestall,
J.C., et al., Usefulness of the
Medical Research Council (MRC) dyspnoea scale as a measure of
disability in patients with chronic obstructive pulmonary disease.
Thorax, 1999. 54(7): p. 581-6.
[return to text]
|
|
26
|
Badgett,
R.G., et al., Can moderate chronic
obstructive pulmonary disease be diagnosed by historical and
physical findings alone? Am J Med, 1993.
94(2): p. 188-96. |
|
27
|
Kelly, C.A.
and G.J. Gibson, Relation between FEV1
and peak expiratory flow in patients with chronic airflow
obstruction. Thorax, 1988. 43(4):
p. 335-6. |
|
28
|
NHLBI/WHO
Workshop Report, Global Initiative for
Chronic Obstructive Pulmonary Disease (GOLD):
Global strategy for the diagnosis, management and prevention of
chronic obstructive pulmonary disease.
April 2001, National Institutes of Health - National Heart, Lung and
Blood Institute: Bethesda, MD. p. 6. |
|
29
|
Wilt, T.J.,
et al., Use of spirometry for case
finding, diagnosis, and management of chronic obstructive pulmonary
disease (COPD). Evid Rep Technol Assess (Summ), 2005(121): p.
1-7. |
|
30
|
Miller,
M.R., et al., Standardisation of
spirometry. Eur Respir J, 2005. 26(2):
p. 319-38. |
|
31
|
Sourk, R.L.
and K.M. Nugent, Bronchodilator
testing: confidence intervals derived from placebo inhalations.
Am Rev Respir Dis, 1983. 128(1):
p. 153-7. |
|
32
|
Pellegrino,
R., et al., Interpretative strategies
for lung function tests. Eur Respir J, 2005.
26(5): p. 948-68. |
|
33
|
British
Thoracic Society, BTS statement on
criteria for specialist referral, admission, discharge and follow-up
for adults with respiratory disease. Thorax, 2008.
63 Suppl 1: p. i1-i16. |
|
34
|
Blanco, I.,
et al., Estimated numbers and
prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency
in European countries. Eur Respir J, 2006.
27(1): p. 77-84. |
|
35
|
American
Thoracic Society/European Respiratory Society,
American Thoracic Society/European
Respiratory Society statement: standards for the diagnosis and
management of individuals with alpha-1 antitrypsin deficiency.
Am J Respir Crit Care Med, 2003. 168(7):
p. 818-900. |
|
36
|
McCord, J.
and S. Borzak, Multifocal atrial
tachycardia. Chest, 1998. 113(1):
p. 203-9. |
|
37
|
National
Heart Lung and Blood Institute,
Morbidity and Mortality: Chartbook on Cardiovascular, Lung, and
Blood Diseases [2004 edition available
http://www.nhlbi.nih.gov/resources/docs/cht-book.htm.
1998, US Department of Health and Institutes of Health: Bethesda,
MD. |
|
38
|
Decramer,
M., et al., Systemic effects of COPD.
Respir Med, 2005. 99 Suppl B: p.
S3-10. |
|
39
|
Holguin, F.,
et al., Comorbidity and mortality in
COPD-related hospitalizations in the
United
States, 1979 to 2001.
Chest, 2005. 128(4): p. 2005-11. |
|
40
|
Borrill, Z.,
et al., Retrospective analysis of
evidence base for tests used in diagnosis and monitoring of disease
in respiratory medicine. BMJ, 2003.
327(7424): p. 1136-8. |
|
41
|
Vathenen,
A.S., et al., High-dose inhaled
albuterol in severe chronic airflow limitation. Am Rev Respir
Dis, 1988. 138(4): p. 850-5. |
|
42
|
Gross, N.J.,
et al., Dose response to ipratropium
as a nebulized solution in patients with chronic obstructive
pulmonary disease. A three-center study. Am Rev Respir Dis,
1989. 139(5): p. 1188-91. |
|
43
|
Higgins,
B.G., et al., Effect of salbutamol and
ipratropium bromide on airway calibre and bronchial reactivity in
asthma and chronic bronchitis. Eur Respir J, 1991.
4(4): p. 415-20. |
|
44
|
Belman,
M.J., W.C. Botnick, and J.W. Shin,
Inhaled bronchodilators reduce dynamic hyperinflation during
exercise in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 1996. 153(3):
p. 967-75. |
|
45
|
Jenkins,
S.C., et al., Comparison of
domiciliary nebulized salbutamol and salbutamol from a metered-dose
inhaler in stable chronic airflow limitation. Chest, 1987.
91(6): p. 804-7. |
|
46
|
Guyatt,
G.H., et al., Bronchodilators in
chronic air-flow limitation. Effects on airway function, exercise
capacity, and quality of life. Am Rev Respir Dis, 1987.
135(5): p. 1069-74. |
|
47
|
Berger, R.
and D. Smith, Effect of inhaled
metaproterenol on exercise performance in patients with stable
"fixed" airway obstruction. Am Rev Respir Dis, 1988.
138(3): p. 624-9. |
|
48
|
Hay, J.G.,
et al., Bronchodilator reversibility,
exercise performance and breathlessness in stable chronic
obstructive pulmonary disease. Eur Respir J, 1992.
5(6): p. 659-64. |
|
49
|
Ram, F.S.
and P. Sestini, Regular inhaled short
acting beta2 agonists for the management of stable chronic
obstructive pulmonary disease: Cochrane systematic review and
meta-analysis. Thorax, 2003. 58(7):
p. 580-4. |
|
50
|
Appleton,
S., et al., Ipratropium bromide versus
long-acting beta-2 agonists for stable chronic obstructive pulmonary
disease. Cochrane Database Syst Rev, 2006.
3: p. CD006101.
[return to text]
|
|
|
Content last updated: |
April 2009 |
|
Page
last updated: |
April 14, 2009 |
|
 |
|
|
|
 |
|
 |
|
Print this page
